Symbiotec Pharmalab stands out as the preferred long-term pick, backed by SBI Securities' 'Subscribe' rating and Master Capital's positive view on its specialised business.
Gold loan market gets crowded: Will new entrants dull incumbents' sheen?
Index funds gain ground as ETFs lose share of India's passive fund market
India's economic growth likely slowed to 7.1% in April-June quarter: Poll
Closing Auction System set for first monthly derivatives expiry test
Stock Market LIVE: Sensex drops 100 pts; Nifty Metal drops 1% as Hindalco, Tata Steel weigh
Skyways Air vs Symbiotec vs Hy-Tech Analysts pick their top IPO bet
Hindustan Copper cracks 7% as govt OFS opens; floor price at 10% discount
Gold loan market gets crowded Will new entrants dull incumbents' sheen?
Annu Projects IPO kicks off: Why analysts are split on this EPC infra firm